GlassScriptPhysician profile
Glenn Kershen
NPI 1013900190
$3,893.42
in general payments reported to CMS, 2019-2025
36 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $295 · 2021: $275 · 2022: $150 · 2023: $412 · 2024: $672 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.73 |
| Education | $382.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $619.16 | 2019-2025 | Xtandi |
| Teleflex LLC | $513.68 | 2021-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $380.81 | 2023-2025 | Erleada, Akeega |
| Medtronic, INC. | $351.48 | 2021-2025 | Interstim |
| Dendreon Pharmaceuticals LLC | $207.13 | 2019-2025 | Provenge |
| Medtronic USA, INC. | $200.58 | 2019-2020 | |
| Pfizer INC. | $191.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $153.02 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Sumitomo Pharma America, INC. | $136.24 | 2024-2025 | Gemtesa |
| Coloplast Corp | $103.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $89.30 | 2024 | Lynparza |
| Antares Pharma, INC. | $86.61 | 2024-2025 | Xyosted |
| Boston Scientific Corporation | $82.35 | 2019 | |
| Janssen Scientific Affairs, LLC | $71.44 | 2020-2025 | Erleada |
| Ferring Pharmaceuticals INC. | $68.01 | 2025 | Adstiladrin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $67.00 | 2022 | |
| Procept Biorobotics Corporation | $66.05 | 2021 | |
| Avyxa Pharma, LLC | $47.97 | 2025 | |
| Endo USA, INC. | $47.08 | 2025 | Xiaflex |
| Calyxo, INC. | $41.46 | 2025 | Cvac Aspiration System |
| Telix Pharmaceuticals | $39.23 | 2025 | Illuccix |
| Bioprotect Medical, INC. | $32.83 | 2025 | Bioprotect Balloon Implant System |
| Blue Earth Diagnostics | $31.77 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $28.42 | 2025 | Personal Catheter Intermittent Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $25.67 | 2024 | |
| Tolmar, INC. | $25.00 | 2023 | |
| Immunitybio, INC. | $24.51 | 2025 | |
| Endo Pharmaceuticals INC. | $23.94 | 2021 | |
| Abbvie INC. | $23.20 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.31 | 2025 | |
| Cook Medical LLC | $17.84 | 2024 | Resonance |
| Photocure INC | $16.80 | 2025 | Cysview |
| Vertex Pharmaceuticals Incorporated | $15.54 | 2025 | |
| Rochester Medical Corporation | $15.25 | 2021 | |
| Olympus America INC. | $14.79 | 2024 | Itind System |
| Bard Peripheral Vascular, INC. | $13.52 | 2025 | Fluency Endovascular Stent Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Kershen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.